A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours

Annals of Oncology

Volumn 17, Issue 7, 2006, Pages 1158-1165

  Dumez, Herlinde ^a   Awada, A ^b   Piccart, M ^b   Assadourian, S ^c   Semiond, D ^c   Guetens, G ^a   de Boeck, G ^a   Maes, R A A ^d   de Bruijn, E A ^a   van Oosterom, A ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c SANOFI   (France)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

CPT 11; Dose escalation; Dose limiting toxicity; Irinotecan; Oral; Powder filled capsule

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; GALLBLADDER CANCER; GASTROINTESTINAL TOXICITY; HUMAN; LIVER CANCER; LIVER METASTASIS; LUNG CANCER; LYMPH NODE METASTASIS; MALE; MELANOMA; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PLEURA CANCER; PRIORITY JOURNAL; SEPTIC SHOCK; SOLID TUMOR; THROMBOCYTOPENIA; THYROID CANCER; URINARY TRACT CANCER; UTERINE CERVIX CANCER; UTERUS CANCER; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TOPOISOMERASE I INHIBITORS;

EID: 33745587557     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl071     Document Type: Article

References (43)

1. Hsiang YH, Liu LF, Wall ME et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 1989; 49: 4385-4389.
2. Jaxel C, Kohn KW, Wani MC et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumour activity. Cancer Res 1989; 49: 1465-1469.
3. Shimada Y, Yoshino M, Wakui A et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993; 11: 909-913.
4. Rothenberg ML, Eckardt JR, Kuhn JG et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128-1135.
5. Pitot HC, Wender DB, O'Connell MJ et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15: 2910-2919.
6. Rougier P, Bugat R, Douillard JY et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-260.
7. Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
8. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
9. Rothenberg ML, Cox JV, DeVore RF et al. A multicentre, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999; 85: 786-795.
10. Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 1999; 35: 54-59.
11. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355: 1041-1047.
12. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
13. Becouarn Y, Gamelin E, Coudert B et al. Randomized multicentre phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 2001; 19: 4195-4201.
14. Scheithauer W, Kornek GV, Raderer M et al. Randomized multicentre phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. J Clin Oncol 2002; 20: 165-172.
15. Souglakos J, Mavroudis D, Kakolyris S et al. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicentre phase II trial. J Clin Oncol 2002; 20: 2651-2657.
16. Castellano D, Gravalos C, Garcia-Alfonso P et al. Phase I/II study of escalating doses of irinotecan (CPT-11) in combination with UFT/folinic acis (FA) in patients with advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2001; 20: Abstr 577.
17. Cassata A, Stani S, Alu M et al. Ongoing phase II trial with two schedules of irinotecan (CPT-11) in combination with capecitabine as first-line chemotherapy in patients with advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2001; 20: Abstr 573.
18. Sleucher N, Tewes M, Achterrath W et al. Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer. Proc Am Soc Clin Oncol 2001; 20: Abstr 561.
19. Lavelle F, Bissery MC, Andre S et al. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 1996; 23: 11-20.
20. Wiseman LR, Markham A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996; 52: 606-623.
21. Abigerges D, Chabot GG, Armand JP et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210-221.
22. Merrouche Y, Extra JM, Abigerges D et al. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: A feasibility study. J Clin Oncol 1997; 15: 1080-1086.
23. Herben VM, Schellens JH, Swart M et al. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumours. J Clin Oncol 1999; 17: 1897-1905.
24. Takimoto CH, Morrison G, Harold N et al. Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients. J Clin Oncol 2000; 18: 659-667.
25. Houghton PJ, Cheshire PJ, Hallman JD 2nd et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumours. Cancer Chemother Pharmacol 1995; 36: 393-403.
26. Thompson J, Zamboni WC, Cheshire PJ et al. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 1997; 3: 423-431.
27. Gerrits CJ, de Jonge MJ, Schellens JH et al. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 1997; 76: 952-962.
28. Borner MM, Schoffski P, de Wit R et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38: 349-358.
29. Thompson J, Zamboni WC, Cheshire PJ et al. Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs 1997; 8: 313-322.
30. Drengler RL, Kuhn JG, Schaaf LJ et al. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumours. J Clin Oncol 1999; 17: 685-696.
31. Dumez H, Awada A, Van Oosterom A et al. A phase I and pharmacokinetic (PK) trial of oral formulation of irinotecan administered daily for 5 days every 3 weeks in patients (Pts) with solid tumours. Proc Am Soc Clin Oncol 2001; 20: Abstr 408.
32. Schoemaker N, Ten Bokkel Huinink WW, Vernillet L et al. A phase I and pharmacokinetic (PK) trial of oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients (pts) with solid tumours. Proc Am Soc Clin Oncol 2001; 20: Abstr 295.
33. Pitot HC, Adjei AA, Reid JM et al. A phase I and pharmacokinetic study of a powder-filled capsule (PFC) formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumours. Proc Am Soc Clin Oncol 2001; 20: Abstr 403.
34. Sharma S, Knight RD, Hollywood E et al. A phase I and pharmacokinetic study of powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 14 days every 3 weeks in patients with advanced solid tumours. Proc Am Soc Clin Oncol 2001; 20: Abstr 407.
35. Chollet DF, Goumaz L, Renard A et al. Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography. J Chromatogr B 1998; 718: 163-175.
36. de Jong FA, Mathijssen RH, de Bruijn P et al. Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection. J Chromatogr B 2003; 795: 383-388.
37. Vanhoefer U, Harstrick A, Achterrath W et al. Irinotecan in the treatment of colorectal cancer: Clinical overview. J Clin Oncol 2001; 19: 1501-1518.
38. Chabot GG, Abigerges D, Catimel G et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 1995; 6: 141-151.
39. Gupta E, Mick R, Ramirez J et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997; 15: 1502-1510.
40. Carmichael J. UFT plus leucovorin vs 5-FU plus leucovorin for metastatic colorectal cancer. Oncology (Huntingt) 1997; 11: 50-52.
41. Hoff PM, Lassere Y, Pazdur R. Tegafur/uracil + calcium folinate in colorectal cancer: Double modulation of fluorouracil. Drugs 1999; 58: 77-83.
42. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001; 19: 4097-4106.
43. Kerr D, Ten Bokkel Huinink W, Bakker J et al. CPT-11 in combination with capecitabine as first-line therapy for metastatic colorectal cancer. Eu J Cancer 2001; 37 (Suppl 6): 296.